Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe Basic Biology of PP2A in Hematologic Cells and MalignanciesTargeting c-MYC by antagonizing PP2A inhibitors in breast cancer.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancerFrom the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesCracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid LeukemiaDiscovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.Clinical significance of in vivo cytarabine-induced gene expression signature in AML.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2ASex chromosome loss and the pseudoautosomal region genes in hematological malignancies.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.OP449 inhibits breast cancer growth without adverse metabolic effects.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.SETting OP449 into the PP2A-activating drug family.Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Therapeutic Targeting of PP2A.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia.SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway.The impact of phosphatases on proliferative and survival signaling in cancer.Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications
P2860
Q26752430-B0142BC2-6F3F-46EF-8139-A4318FC6C3A8Q28088697-F1710225-39EC-4B0A-BAB0-EA959EA2E834Q33835127-FC4D4A84-B638-4036-8AAF-DAE4B00FCB9FQ33977247-D882B3C6-F8FA-48FB-B29F-B6AB3A5C93F6Q34043449-97168C68-AF86-4047-ABB1-10ACD55A8FBBQ34730329-E33F9D88-E6C9-43D3-B7FD-F481A485FFACQ35037262-A9ECCD3C-2A60-404B-AB76-2FF358BCF4E7Q35828517-5E4C2E28-309F-4C1E-A0F6-74B8CEB10327Q36275673-6A54120E-CEEB-4051-95D9-5134E79B4DC7Q36693136-CF892E1A-8466-4195-BF59-C872DF171B54Q36729492-DEE457E2-4121-40D6-88B8-5FC4F1E6A56FQ37687827-FB6F971A-870F-430A-9B71-DAC360EFA6A0Q37708933-44DAD6DF-49AD-4C5A-AD31-BF57FBF84B44Q38613399-0F871523-4518-4A38-82C2-526A7F991B3CQ38617799-D7C8D6A5-823E-43C7-815A-28B4095BD5A5Q38675400-7D5ADAA4-470A-43BF-BB6B-7B8DC86851F8Q38678579-25B1226B-DDC9-420D-97DF-0A48D8FF4624Q38810636-92A03A28-2DAA-4927-9979-47D1072E0600Q38891984-D4021478-A42F-4406-B75F-0D15FBA9841BQ40859498-43CE9A59-FEDE-4D7D-A0AD-55928ACE5473Q41553595-B412812E-6095-46A5-9DB8-781878D382C9Q42573854-82A03788-1D0F-43C0-8DE5-2FB6381D8625Q43094665-E351A592-D6A4-4C0B-888C-626A756D7F2CQ44320317-BB2E078C-C5FF-473C-9965-608E33C14844Q47137224-A68A165C-8612-4EFF-9F31-B39A5DFF5C14Q47271622-926EB209-BE35-4234-A09F-B8BE3A177450Q47436859-BA2C8BAD-8277-47C5-BFD5-F9951FBC7814Q48064023-A3445DD1-385B-4A13-A003-4437DC216660Q51039769-2A344B6B-96E0-451E-A321-90A37EC54791Q51414305-627EDBB5-893D-4791-B835-7E976A55F7B2Q54112403-C292CE8D-9271-49A0-9264-C795F5C92DDAQ58374470-79EAA509-C86E-4061-934F-4C02F78AB973
P2860
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@en
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@nl
type
label
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@en
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@nl
prefLabel
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@en
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@nl
P2093
P2860
P50
P1476
Antagonism of SET using OP449 ...... esistance in myeloid leukemia.
@en
P2093
Anupriya Agarwal
Christopher A Eide
Dale J Christensen
Jessica Oddo
María D Odero
Michael P Vitek
Rosalie Sears
Ryan J MacKenzie
P2860
P304
P356
10.1158/1078-0432.CCR-13-2575
P407
P577
2014-01-16T00:00:00Z